CAPO SYMPOSIUM

CLINICAL & TRANSLATIONAL RESEARCH IN PNEUMONIA, INFLUENZA AND EMERGING RESPIRATORY PATHOGENS: DEFINING A RESEARCH AGENDA FOR TODAY AND TOMORROW

SPEAKERS

STEFANO ALIBERTI, MD
Is assistant professor in respiratory medicine at the University of Milan Bicocca, Milan, and consultant at the San Gerardo University Hospital, Monza, Italy. After his medical training at the University of Milan, he spent one year at the Division of Infectious Diseases at the University of Louisville, KY, USA, working as visiting research fellow on Community-Acquired Pneumonia Organization database. His research and clinical interests are in both acute and chronic respiratory infections, including community-acquired pneumonia, severe sepsis and non-cystic fibrosis bronchiectasis. Stefano Aliberti has been awarded prestigious young investigator awards and has published over 60 articles on CAP in peer-reviewed journals since 2006. He is heavily involved in international respiratory societies and he is currently head of Respiratory Infections Assembly of the ERS.

ANTONIO ANZUETO, MD
Is Chief of the Pulmonary Section at the VA's South Texas Veterans Health Care System and Professor at the University of Texas Health Science Center at San Antonio. He plays a major role in the Foundation's clinical research programs, Dr. Anzueto has sought out new research that would be of benefit to his veteran patients. He currently serves as Principal Investigator on numerous clinical research studies/ Dr. Anzueto and his Pulmonary research group are currently conducting clinical studies that involve treating conditions that range Chronic Obstructive Pulmonary Disease, pneumonia, acute respiratory distress/injury, to septic shock.
STEPHEN ASTON, MBChB, MRCP, DTM&H
Is Wellcome Trust Clinical PhD Fellow. He was a clinical research fellow at Liverpool School of Tropical Medicine and was initially involved in large collaborative project investigating the pathophysiology of severe pandemic influenza. He started specialist registrar training in infectious diseases and general internal medicine in 2010 and in 2012 secured a Wellcome Trust Clinical PhD Training Fellowship to study pneumonia in Malawian adults. His main research interests are the diagnosis and management of severe respiratory tract infection in low-resource settings, particularly in HIV-infected adults. In his current PhD project he is recruiting a large prospective cohort of adults hospitalized with pneumonia in Malawi with the aim of identifying factors predictive of adverse outcome that may then inform patient triage and early management strategies.

FRANCESCO BLASI, MD, FERS
Is Professor of Respiratory Medicine and Vice Chairman of the Department of Pathophysiology and Transplantation at the University of Milan, Italy as well as Director of the School of Speciality in Respiratory Diseases at the University of Milan, and Head of Cardiothoracic Unit IRCCS Fondazione Ca Granda Ospedale Maggiore Milan. His research interests include the effect of atypical bacterial infection on cellular immunity in chronic bronchitis, and the role of atypical bacteria and viral infection in asthma onset. He is also interested in the role of antibiotics in the treatment of chronic obstructive pulmonary diseases (COPD) exacerbations and asthma. He is actively working on pneumonia and tuberculosis research trials. Professor Blasi has published more than 230 papers in international journals.

JOSE BORDON, MD, PhD, AAHIVS
Is Lead Faculty of Infectious Diseases at Providence Hospital in Washington, D.C. and a board certified infectious disease specialist, focusing on treatment of individuals with HIV infections. He offers patients high quality care in a professional and compassionate manner. Among his notable affiliations, Dr. Bordon is on the Editorial Board of Case Reports in Pulmonology and a Journal reviewer for numerous journals, including Clinical Infectious Diseases. His areas of interests include HIV infections, viral Hepatitis, and Hepatitis C.

Elisabet V. Caler, Ph.D, M.Phil
is Program Director at the National Heart, Lung and Blood Institute in the Division of Lung Diseases and served as Adjunct Assistant Professor, Microbiology and Immunology at the University of Maryland School of Medicine. Her main interest and focus are in Public Health, Genomics and Microbial Ecology in what pertains to Respiratory System and Lung Health. Her research interests include AIDS, tuberculosis, parasite genomics, Lung Microbiome, and Metagenomics.
James Chalmers, MD
Is a Wellcome Trust Postdoctoral Fellow and currently works in the Division of Molecular Microbiology in the College of Life Sciences, University of Dundee. His research interests are in translational and clinical aspects of respiratory infections and the mechanisms of bacterial colonization on chronic lung disease. He is a current member of the British Thoracic Society Science and Research committee, the European Respiratory Society long range planning committee and the American Thoracic Society Microbiology Tuberculosis and Pulmonary Infections program committees.

Patrick Charles, PhD, MB BS, FRACP
Is a physician in both Infectious Diseases and General Internal Medicine at Austin health in Melbourne, Australia. He completed his PhD in CAP several years ago, which involved a very large etiology study, and also the development of the SMART-COP severity scoring system for the prediction of need for ICU admission in patients with CAP. His research interests include the emergence of antibiotic-resistance pathogens, community-acquired pneumonia-aetiology, treatment choices and severity assessment, nursing home-acquired infections, pandemic H1N1 influenza, improving antibiotic use and Dengue fever immunization.

Nathan C. Dean, MD
Is Internal Medicine Professor and Chair of the Lower Respiratory Tract Infection Team for Intermountain Healthcare as well as Section Chief of Pulmonary and Critical Care Medicine at Intermountain Medical Center and LDS Hospital in Utah. His research has focused on improving pneumonia care and measurements of clinical outcomes. His interests include validating severity and triage scoring systems for pneumonia. He has also participated in multi-national, prospective randomized trials of new therapies for severe community acquired pneumonia. His ongoing projects include development and implementation of real time electronic decision support for emergency department patients with pneumonia. As an investigator he has authored or co-authored 50 peer reviewed publications. He serves as an ad hoc reviewer for multiple journals, including Chest, the American review of Respiratory and Critical Care Medicine, Respirology, European Respiratory Journal, Critical Care Medicine, Clinical Infectious Diseases, Journal of General Internal Medicine and JAMA.
Charles Feldman, PhD, MB BCH
Is Professor of Pulmonology, Chief Physician, Head Pulmonology Division of the University of the Witwatersrand, Johannesburg South Africa. He is President of the South African Pulmonology Society, Chairperson JHB Regional Branch of the Critical Care Society of South Africa, International Governor for South African for the American College of Chest Physicians. His research interest is in the field of community-acquired pneumonia and in particular pneumococcal pneumonia. In addition to being part of large international clinical collaborations recruiting cases of community-acquired pneumonia he has also contributed to basic research studies, investigating the effects of various pneumococcal virulence factors on human ciliated epithelium as well as investigating the effects of antibiotics on pneumococcal growth and expression of virulence factors. He has a number of publications in books and book chapters as well as more than 170 articles in indexes, peer reviewed journals.

Thomas M. File Jr., MD,MS
Is Chief of the Infectious Disease Service and Director of HIV Research at Summa Health System in Akron, Ohio, and Professor of Internal Medicine and Master Teacher at the Northeastern Ohio Universities College of Medicine in Rootstown, Ohio. He is a Fellow of the American College of Physicians, the Infectious Diseases Society of America, and the American College of Chest Physicians. He is on the Board of Directors of the National Foundation for Infectious Diseases, serves on the Editorial Board of Journal of Respiratory Disease and is Editor-in-Chief of Infectious Diseases in Clinical Practice, as well as a member of many other professional societies. His primary research interests include community-acquired respiratory tract infections, bacterial resistance in respiratory infections, infectious in patients with diabetes, and evaluation of new antimicrobial agents. He has published more than 200 articles, abstracts, and textbook chapters.

Thomas Holland, MD, MSC-GH
Is Assistant Professor of Medicine at the Duke University Medical Center. He completed a Fogarty International Clinical Research Fellowship in Eldoret, Kenya where he investigated the prevalence of rheumatic heart disease. During his internal medicine residency he was elected to spend several months working with a primarily Aboriginal population in the Australian Outback on a Global Health Rotation. He has a commitment to a career advancing the care of underserved populations. His research interests include rheumatic heart disease in Kenya, acute infectious disease, chronic cardiovascular diseases, improving inadequate epidemiological data.
Robert R. Kelley, PhD, MS
Is Assistant Professor of Medicine in the University of Louisville School of Medicine, Division of Infectious Diseases. Although, his background is in computer engineering and computer science, Dr. Kelley's research focuses on two major categories: infectious diseases and health informatics. In the infectious diseases our group conducts research on a wide range of topics including pneumonia, influenza, HIV, travel medicine, vaccines and immunization, and refugee health. In health informatics, he is researching methods to improve data validation for clinical datasets, visualization techniques for clinical data, and data mining techniques for clinical data. Researching and developing Clinical Data Management tools to assist study coordinators with capturing study data and to assist principle and secondary investigators with retrieving datasets for analysis and Clinical Data Analysis tools for automating study data analysis.

GianLuigi Li Bassi, MD
Is a physician at the University of Barcelona. He is a specialist in anesthesia and critical care. He takes part in the animal model line and his research focuses on finding new strategies to reduce the incidence of intubation-associated pneumonia. His research interest focuses on devising and evaluating new devices and strategies to prevent intubation-associated pneumonia and translate the findings to ICU patients. In particular, he is interested in finding preventive approaches to mint physiologic airway sterility, following tracheal intubation.

Gustavo Lopardo, MD
Is Professor of Infectious Diseases, University of Buenos Aires and Infectious Diseases Clinical Consultant, Hospital Municipal Dr Bernardo Houssay de Vicente López and FUNCEI, President of the Argentinean Society for Infectious Diseases Buenos Aires, Argentina. Professor Lopardo graduated with honors from the University of Buenos Aires Medical School in Argentina in 1986. In addition to his current roles at the University of Buenos Aires and the Hospital Municipal Dr Bernardo Houssay de Vicente López, he is also a staff member of Fundación del Centro de Estudios Infectológicos (FUNCEI), also in Buenos Aires. He is the President of the Argentinean Society for Infectious Diseases. For more than 25 years, he has been involved in many aspects of infectious disease management, including the clinical care of patients, lecturing and clinical research. His special interest is in respiratory tract infections including community-acquired pneumonia, where he has undertaken extensive research.
Carlos Luna, MD
Is Full Professor of Pulmonary and Internal Medicine at the University of Buenos Aires, Argentina, Director of the Pulmonary Medicine Fellowship Program and Head of the Pulmonary Diseases Division, Department of Internal Medicine at the Hospital de Clínicas, Universidad de Buenos Aires. He is also the Coordinator of the Selection and Evaluation Committee of the Postgraduate Training Program in Pulmonary Medicine at the Faculty of Medicine, Universidad de Buenos Aires. His main academic interests are pulmonary infections, including epidemiology, diagnoses, therapy and prevention and more specifically, community acquired pneumonia and nosocomial pneumonia, including ventilator associated pneumonia. He is an active member of the American Thoracic Society. He is the Chief Editor of the Revista Americana de Medicina Respiratoria (American Journal of Respiratory Medicine), edited in Argentina: he serves as a member of the Editorial Board of Chest, Clinical Pulmonary Medicine, Seminars in respiratory and Critical Care Medicine, Journal Brasileiro de Pneumologia, Revista de la Sociedad Mexicana de Cirugía de Tórax y Neumología, Current Respiratory Medicine Reviews and Infection & Drug Resistance.

Rosario Menéndez, MD
Is a pulmonologist at Hospital La Fe, Section Chief of Pneumology Hospital Universitari i Politècnic Faith, Group Leader of respiratory Infections Health Research Institute Faith. She is on the Organizing Committee of Microbiology, Tuberculosis and Lung Infections of the American Thoracic Society. Her research interests includes the epidemiology of pneumonia mainly in the inflammatory response, biological markers of infection and inflammation, development of immunocompetence and genetic polymorphisms of pneumonia and mucosal colonization by multi-resistant bacteria in critically ill patients. She has published 86 articles in scientific journals.

Matthew Moore, MD, MPH, CDC
Is Lead Medical Epidemiologist at the Centers for Disease Control Pneumococcal Disease Epidemiology, Active Bacterial Core surveillance (ABC's) Program. He is trained in internal medicine and infectious diseases with additional training in CDC's Epidemic Intelligence Service Program. He is the CDC's principal investigator on the evaluation of the effectiveness of 13-valent pneumococcal conjugate vaccine.
Michael S. Niederman, MD
Is Professor and Vice-Chairman in the Department of Medicine in SUNY at Stony Brook University. He is on the editorial boards of Chest, Critical Care Medicine, Critical Care Medicine and Intensive Care Medicine. He has authored over 350 research articles, reviews and book chapters. He is a member of the American Thoracic Society, American College of Chest Physicians and Society of Critical Care Medicine. He has been honored for his work in pneumonia by several national and international organizations. His research interests include improving the management of patients with pneumonia including the writing of guidelines for pneumonia management on behalf of several national and international organizations, and new therapies for pneumonia focusing on optimizing the treatment of patients infected with antibiotic-resistant pathogens.

David Oldach, M.D., FIDSA
Is Chief Medical Officer at David Oldach joined Cempra Pharmaceuticals. Between 2006 and 2011, Dr. Oldach directed clinical research at Gilead Sciences, Inc., where his drug development experience ranged from IND/first-in-human trial development and execution through NDA-supportive Phase 3 protocol development and execution. Dr. Oldach received his Medical Degree, Magna Cum Laude, from the University of Maryland School of Medicine and completed a residency in Internal Medicine at the Massachusetts General Hospital. He completed an Infectious Disease Fellowship at Johns Hopkins University School of Medicine, serving under John Bartlett. His academic clinical research included studies in community-acquired pneumonia and surgical infections, as well as HCV pathogenesis. At the time of his transition from academic medicine to industry, Dr. Oldach was a tenured Associate Professor of Medicine at the University of Maryland School of Medicine and served as the Infectious Diseases Section Chief in the Baltimore Veterans Administration Hospital.

Diana Otczyk, PhD
Is a Senior Research Fellow at Griffith University School of Medicine, Australia. Dr Diana Otczyk is a member of the founding team for pneumonia. In the role as Senior Editor, she is responsible for manuscript handling and the review process to publication. She is involved in formulating pneumonia’s editorial policy and standards and has a wider interest in publishing ethics. Dr Otczyk is a Senior Research Fellow in the School of Medicine at Griffith University. Her research interests are in immunological aspects of COPD and otitis media, including vaccine development, and worked for many years in the management of clinical trials. She has published in peer reviewed journals and presented her work at international scientific and medical conferences.
Paula Peyrani, MD
Is Assistant Professor of Medicine and the Director of the Clinical Research Unit at the Division of Infectious Disease, University of Louisville, Medical Director and Project Director of the HIV Clinic, Ryan White Care Act. Dr. Peyrani coordinates the research teams in the Division of Infectious Diseases at the University of Louisville, she educates new researchers and communicates with investigators in different parts of the world. Since 2005 she has been working in the Data and Statistical Coordinating Center under Dr. Julio Ramirez's monitorship, assisting with data quality and data management for various studies. She mentors local and international junior investigators and interacts with investigators as part of the Community-Acquired Pneumonia Organization (CAPO) international network. Her research interests include HIV, community-acquired pneumonia, ventilator-acquired pneumonia.

Julio Ramirez, MD, FACP
Is the Chief of the Division of Infectious Diseases, Professor of Medicine, Director of the Infectious Diseases Fellowship Training Program, and Founding Director of the Global Health Initiative at the University of Louisville School of Medicine in Louisville, Kentucky. He is also a Fellow in the American College of Physicians. He is board certified in internal medicine and holds subspecialty certification in infectious diseases. Dr Ramirez's areas of research interest include: (1) clinical research in the field of pneumonia, and (2) basic research in the field of diagnosis and pathogenesis of infections due to atypical pathogens. Dr. Ramirez is the recipient of the 2013 European Respiratory Society Presidential Award in recognition of his outstanding contribution to research in the field of respiratory infections.

Jordi Rello, MD, PhD
Is Chief of the Critical Care Department, Hospital Vall d’Hebron, Barcelona, Spain. He serves as the Head of the Working Group on Pneumonia and Director of Research Group of CIBERES. He is a Consultant of pharmaceutical companies, serving in editorial Boards of many journals and advisory boards, as the ATS/IDSA Committee for VAP, HAP and HCAP guidelines. He serves as a member of Clinical Advisory Board at Kenta Biotech Ltd. He was awarded with Young Investigator Awards of the American College of Chest Physicians and co-recipient of the Emmanuel Wolinski Award (IDSA). He has published more than 250 articles and co-edited many books. He pioneered studies on prevention and control of device-related infections and in the therapy of VAP.
Marcos Restrepo, MD, MSc, FACCMP
Is Assistant Professor in the Department of Medicine, Divisions of Pulmonary/Critical Care Medicine at the University of Texas Health Science Center at San Antonio. He is an investigator at VERDICT, a health services research center for the Veterans Administration at the South Texas Veterans Health Care System, Audie L. Murphy Division. He is board-certified in internal medicine, infectious disease, pulmonary disease and critical care medicine and is a Fellow in the American College of Chest Physicians. His research interests are the evaluation of the impact of immunomodulatory agents in patients with sepsis and pneumonia. He is interested in the application and implementation of evidence-based guidelines into clinical practice in order to improve health outcomes and quality of care of patients critically ill in the intensive care unit with respiratory infections.

Yuichiro Shindo, MD, PhD
Is Assistant Professor at Nagoya University Graduate School of Medicine and at the Institute for Advanced Research, Nagoya University. His research interests include molecular epidemiological characteristics of Klebsiella pneumoniae, immunology protocols, respiratory organ internal medicine, risk factors bacterial antibiotic resistance, isolation of drug resistant pathogens, pneumonia pathogen characterization. He is a member of the Japanese Society of Internal Medicine, The Japanese Respiratory Society, The Japanese Association for Infectious Diseases.

Antoni Torres, MD
Is Professor in Medicine at the University of Barcelona. He is considered a physician of reference both nationally and internationally in lung infections, including pneumonia, chronic obstructive pulmonary disease (COPD), bronchiectasis, immunocompromised patients, weaning, noninvasive ventilation and acute respiratory distress syndrome. He has published more than 200 original articles he has an accumulated impact factor of more than 1390 and his published articles have received approximately 13,000 citations. He leads the research group on Management and prevention of infectious, interstitial and tumoral lung diseases of the August Pi i Sunyer Institute of Biomedical Research (IDIBAPS). His research interests include community-acquired and intrahospital respiratory infections, community-acquired respiratory infections, noninvasive withdrawal of mechanical ventilation, artificial ventilation, acute respiratory distress syndrome and animal model of severe pneumonia.
Grant Waterer, MB BS, FRACP
Is Professor of Medicine at the University of Western Australia and Adjunct Professor of Medicine at Northwestern University, Chicago. He is also a consultant respiratory physician at Royal Perth Hospital. He is on the editorial board of the American Journal of Respiratory and Critical Care Medicine, Chest, the European Respiratory Journal, Therapeutic Advances in Respiratory Medicine, PlosOne and Medicina Respiratoria. He is currently co-chair of the American Thoracic Society (ATS) and Infectious Diseases Society of North America statement in community-acquired pneumonia, the program chair elect for the Microbiology, Tuberculosis, and Pulmonary Infectious Chapter of ATS and the chair of the International COPD Network. He has over 120 peer-reviewed publications. His main areas of interest are in pulmonary infections, including pneumonia and exacerbations of COPD.

Brandon J. Webb, MD
Is an Adjunct Assistant Professor of Medicine at the University of Utah School of Medicine and infectious disease physician at Intermountain Healthcare. His research interests include fungal infections, aspergillosis, antibiotic resistance, antimicrobial stewardship, bacterial pneumonia and transplant infections.

Tobias Welte, MD
Is Professor of Pulmonary Medicine and Head of the Department of Pulmonary and Infectious Diseases at Hannover University School of Medicine. He is Vice-President of the German Society of Sepsis and President of the German Society of Pneumology. He is also on the executive board of the German Center of Lung Research, the Internal board of the German Center of Infectious Diseases and on the board of 'Atemwegsliga' and is a member of the working group on mechanical ventilation for the German Society of Critical Care and the spokesman of the review panel of the German Research Foundation. He is the chairman of the German Network for Community-acquired pneumonia (CAPNET) and an advisory board member of the German Sepsis Network (SEPNET). He is on the editorial board of the European Respiratory Journal and Therapeutic Advances in Respiratory Disease, editor of Der Pneumologe and Intensivmedizin Update and co-editor of Pneumologie und Intensivmedizin and European Respiratory Topic. He has published around 500 papers in peer-reviewed journals and contributed chapters to over 100 books. His research interests include the role of trefoil factor family (TFF) peptides in hypersecretion in patients with obstructive airway disease, and the functional characterization of cathepsin K and L in fibroblasts and epithelial cells in the lung.
Timothy L Wiemken, PhD, MPH

Is an Assistant Professor of Medicine in the University of Louisville School of Medicine, Division of Infectious Diseases. Dr. Wiemken works closely with many infection prevention and hospital epidemiology departments throughout the country. He is currently on the Society for Healthcare Epidemiology of America (SHEA) National Guidelines Committee and the Association for Professionals in Infection Control and Epidemiology (APIC) Annual Conference Committee. He has authored and co-authored numerous guidelines and book chapters on infectious diseases and infection prevention and over 40 peer-reviewed journal articles related to infectious disease epidemiology. His research interests include developing new ways to prevent the transmission of infectious disease through the application of both qualitative and quantitative methods. Pneumonia, tuberculosis, healthcare-associated infections, disease surveillance, HIV, social networks, infectious diseases dynamics and modeling and medical education.

Richard G Wunderink, MD, FCCP

Is Professor in Medicine in the Pulmonary and Critical Care Division of Northwestern University Feinberg School of Medicine, faculty in the Northwestern University Center for Genetic Medicine and Director, Medical Intensive Care Unit, Northwestern Memorial Hospital in Chicago, Illinois. He is on the editorial board of Chest, the American Journal of Respiratory and Critical Care Medicine, and the Proceedings of the American Thoracic Society. He is a member of the Medical Peer review Committee, Reviewer of The Netherlands Organization for Health Research and Development (ZonMW). His research interests revolve around understanding the risk factors, including host genetic risk, and improving outcomes of critically ill patients with serious infections. This includes severe community-acquired pneumonia, sepsis of all causes, and nosocomial infections, particularly ventilator-associated pneumonia.